Showing results (231-240 of 241) with videos related to
Sort By:
Pageof 25
JCI Insight|February 7, 2023
CYB5R3 in type II alveolar epithelial cells protects against lung fibrosis by suppressing TGF-β1 signalingMarta Bueno, Jazmin Calyeca, Timur Khaliullin, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosisNico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.Journal of Medicinal Chemistry|May 31, 2017
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart FailureMarkus Follmann, Jens Ackerstaff, Gorden Redlich, et al.American Journal of Respiratory Cell and Molecular Biology|December 22, 2017
Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell DiseaseKarin P Potoka, Katherine C Wood, Jeffrey J Baust, et al.Journal of Medicinal Chemistry|April 19, 2021
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)Michael G Hahn, Thomas Lampe, Sherif El Sheikh, et al.Journal of Medicinal Chemistry|April 11, 2023
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant HypertensionAlexandros Vakalopoulos, Frank Wunder, Ingo V Hartung, et al.British Journal of Pharmacology|September 16, 2021
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptorsStephen Ph Alexander, Doriano Fabbro, Eamonn Kelly, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 12, 2025
Soluble guanylate cyclase stimulation improves cardiac function and mitochondrial activity in a rat model of early-stage heart failure with preserved ejection fractionXocas Vázquez-Abuín, Sandra Moraña-Fernández, Alana Aragón-Herrera, et al.British Journal of Pharmacology|December 20, 2023
The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptorsStephen P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.Pageof 25